New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a clinect nz pty ltd - haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) - injection with diluent - 10 mcg/0.5ml - active: haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) excipient: hydrochloric acid sucrose trometamol sodium chloride water for injection - act-hib is indicated for use in infants from 2 months to 5 years of age for active immunisation against invasive disease caused by the haemophilus influenzae type b.

Uganda - Ingliż - National Drug Authority

serum institute of india pvt ltd - diphtheria + tetanus + pertussis + hepatitis b + haemophilus influenzae type b conjugate + aluminium phosphate - parenteral ordinary vials - ? 25 lf (? 30 iu) + ? 2.5 lf (? 40 iu) + ? 16 ou (? 4.0 iu) + ? 10 mcg + ? 10 mcg + ? 1.25 mg/dose

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, inactivated bordetella pertussis, hepatitis b surface antigen (rdna), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; diphtheria - vaccines - quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis b and invasive disease caused by haemophilus influenzae type b and for booster immunisation of young children during the second year of life.the use of quintanrix should be determined on the basis of official recommendations.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - haemophilus influenzae type b, conjugate with tetanus protein - pdr+solv for soln for inj - 10mcg/0.5m microgram/ml - hemophilus influenzae b vaccines

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

sanofi pasteur - haemophilus influenzae type b, conjugate with tetanus protein - pdr+solv for soln for inj - 10mcg/0.5m microgram/ml - hemophilus influenzae b vaccines

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc; distributor: zuellig pharma corporation - diphtheria, tetanus, pertussis (acellular poliomyelitis (inactivated) vaccine and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension and powder for suspension for injection (im) - after reconstitution, each dose (0.5 ml) contains: diphtheria toxoid tetanus toxoid bordetella pertussis antigen pertussis toxoid filamentous hemagglutinin poliovirus (inactivated) >30 iu >40 iu polysaccharide influenzae type b conjugated to tetanus protein of haemophilus 10 mcg 18-30 mcg 25 mcg 25 mcg type i poliomyelitis virus (inactivated) 40 d antigen units type ii poliomyelitis virus (inactivated) 8 d antigen units type iii poliomyelitis virus (inactivated) 32 d' antigen

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: zuellig pharma corporation - diphtheria, tetanus, pertussis (acellular component), hepatitis b, poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid' tetanus toxoid ' bordetella pertussis antigen pertussis toxoid' filamentous hemagglutinin' poliovirus (inactivated)2.3 type i (mahoney) strain nlt 20 iu nlt 40 iu hepatitis b surface antigen haemophilus influenzae type b polysaccharide phosphate) 10 mcg (polyribosylribitol 12 mcg conjugate to tetanus protein 22-36 mcg 25 mcg 25 mcg 40 d antigen units type ii (mef-1) strain" type iii (saukett) strain1 8 d antigen units 32 d antigen units 'adsorbed on aluminium hydroxide, hydrated (al(oh)3) 2produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology 3adsorbed on aluminium phosphate (aipo4) *propagated in vero cells

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: medical vaccines online deliveries; distributor: medical vaccines online deliveries - diphtheria, tetanus, pertussis, hepatitis b (rdna) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diptheria toxoid.............<25 lfl> 30 i.u.) tetanus toxoid.............> 2.5 lf> 40 i.u.) . bordetella pertussis (whole cell)............< 16 ou (>4 1.u.) . hepatitis b (rdna)....................10 mcg haemophilus influenzae congugate vaccine............ > 10 mcg